You are in: eMedicine Specialties > Emergency Medicine > EAR, NOSE, AND THROAT GingivitisArticle Last Updated: Oct 15, 2008AUTHOR AND EDITOR INFORMATIONAuthor: James M Stephen, MD, FAAEM, FACEP, Assistant Professor, Tufts University School of Medicine; Attending Physician and Director of Medical Informatics, Department of Emergency Medicine, Associate Director, Kiwanis Pediatric Trauma Service, Tufts Medical Center James M Stephen is a member of the following medical societies: American Academy of Emergency Medicine and American College of Emergency Physicians Editors: Michael Glick, DMD, Professor and Acting Chair, Department of Diagnostic Sciences, New Jersey Dental School, University of Medicine and Dentistry of New Jersey; Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine; Mark W Fourre, MD, Program Director, Department of Emergency Medicine, Maine Medical Center; Associate Clinical Professor, Department of Surgery, University of Vermont School of Medicine; John D Halamka, MD, MS, Associate Professor of Medicine, Harvard Medical School, Beth Israel Deaconess Medical Center; Chief Information Officer, CareGroup Healthcare System and Harvard Medical School; Attending Physician, Division of Emergency Medicine, Beth Israel Deaconess Medical Center; Steven C Dronen, MD, FAAEM, Director of Emergency Services, Director of Chest Pain Center, Department of Emergency Medicine, Ft Sanders Sevier Medical Center Author and Editor Disclosure Synonyms and related keywords: gingivitis, gum swelling, swollen gums, bleeding gums, gum disease, acute necrotizing ulcerative gingivitis, periodontal disease, ANUG, trench mouth, inflammation of the gingiva, plaque, bacterial plaque, gum swelling, gingival tissue, gingiva, acute infectious gingivitis, Prevotella intermedia, alpha-hemolytic streptococci, Actinomyces species, noma, cancrum oris, chronic gingivitis, blood dyscrasias, inadequate oral hygiene, halitosis, gingival hyperplasia, gingivostomatitis INTRODUCTIONBackgroundGingivitis is an inflammatory process limited to the mucosal epithelial tissue surrounding the cervical portion of the teeth and the alveolar processes. Gingivitis has been classified by clinical appearance (eg, ulcerative, hemorrhagic, necrotizing, purulent), etiology (eg, drug-induced, hormonal, nutritional, infectious, plaque-induced), and duration (acute, chronic). The most common type of gingivitis is a chronic form induced by plaque. Acute necrotizing ulcerative gingivitis (ANUG, ie, trench mouth) is an acute infectious gingivitis. The term trench mouth was coined in World War I when ANUG was common among trench-bound soldiers. PathophysiologyThe most common type of gingivitis involves the marginal gingiva and is brought on by the accumulation of microbial plaques in persons with inadequate oral hygiene. Gingivitis proceeds through an initial stage to produce early lesions, which then progress to advanced disease. The initial stage of an acute exudative inflammatory response begins within 4 or 5 days of plaque accumulation. Both gingival fluid and transmigration of neutrophils increase. Deposition of fibrin and destruction of collagen can be noted in the initial stage. At approximately 1 week, transition to early lesions is marked by the change to predominately lymphocytic infiltrates. Monocytes and plasma cells also may be present. With time, lesions become chronic and are characterized by the presence of plasma cells and B lymphocytes. As chronic local inflammation progresses, pockets develop where the gingiva separates from the tooth. These pockets deepen and may bleed during tooth brushing, flossing, and even normal chewing. As this persistent inflammation continues, periodontal ligaments break down and destruction of the local alveolar bone occurs. Teeth loosen and eventually fall out. ANUG is a completely different syndrome caused by acute infection of the gingiva with organisms such as Prevotella intermedia, alpha-hemolytic streptococci, Actinomyces species, or any of a number of different oral spirochetes. ANUG may result in accelerated destruction of affected tissues, as well as local or systemic spread of infection. Noma (cancrum oris) is a syndrome in which ANUG spreads beyond the gingiva. The infection invades local tissues of the mouth and face. FrequencyUnited StatesFrequency is difficult to determine because of the lack of agreement on measurement criteria. Many people believe that gingivitis begins in early childhood and that 9-17% of children aged 3-11 years have gingivitis. At puberty, prevalence rises to 70-90%. In recent years, periodontal disease, the endpoint of chronic gingivitis, slowly has decreased among adult Americans. ANUG may be a clinical problem in immunocompromised patients during chemotherapy. Gingivitis and resulting periodontal disease are seen more frequently in patients with either diabetes or HIV. InternationalStudies in Australia, Sweden, England, and Switzerland report gingivitis in 48-85% of children aged 3-6 years, but whether this range reflects population differences or whether it is due to different criteria used to define the disease is difficult to know. In adolescence, incidence around the world is comparable to US data (70-90%). ANUG may be found in areas where those at risk, particularly children, face poor living conditions. Recent publications show several cases in areas such as Nigeria, where ANUG and noma were observed in children younger than 14 years.1 Mortality/MorbidityPeriodontal disease has been shown in some studies to be an associated factor in coronary artery disease (CAD) and cerebrovascular disease/ischemic stroke.2, 3, 4 This association with CAD has not been shown in all studies. Periodontal disease in pregnancy has been associated with an increase in preterm birth.5 Periodontitis in a person with diabetes has been associated with exacerbation of both conditions.6, 7
Sex
Age
CLINICALHistoryHistorical findings depend on whether the patient has chronic gingivitis or ANUG.
Physical
Causes
DIFFERENTIALSAdrenal Insufficiency and Adrenal Crisis HIV Infection and AIDS
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Drug Name | Penicillin VK (Veetids) |
|---|---|
| Description | DOC in patients with ANUG who are not allergic to penicillin. |
| Adult Dose | 500 mg PO qid for 10 d |
| Pediatric Dose | <12 years: 25-50 mg/kg/d PO divided q6-8h; not to exceed 3 g/d (250 mg = 400,000 U) >12 years: Administer as in adults |
| Contraindications | Documented hypersensitivity |
| Interactions | Probenecid may increase effectiveness by decreasing clearance; tetracyclines are bacteriostatic, causing a decrease in the effectiveness of penicillins when administered concurrently |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in renal impairment |
| Drug Name | Erythromycin (EES, Ery-Tab, Erythrocin) |
|---|---|
| Description | Alternative DOC for patients allergic to penicillin. |
| Adult Dose | 1-2 h before the procedure: 1 g PO 6 h after initial dose: 500 mg PO 250 mg erythromycin stearate/base (or 400 mg ethylsuccinate) q6h 1 h ac, or 500 mg q12h Alternatively, 333 mg q8h; increase, depending on infection severity, up to 4 g/d |
| Pediatric Dose | 2 h prior to procedure: 20 mg/kg PO 6 h after initial dose: 10 mg/kg PO Age, weight, and severity of infection determine proper dosage 30-50 mg/kg/d (15-25 mg/lb/d) in divided doses; double the dose for severe infection |
| Contraindications | Documented hypersensitivity; hepatic impairment |
| Interactions | Coadministration may increase toxicity of theophylline, digoxin, carbamazepine, and cyclosporine; may potentiate anticoagulant effects of warfarin; coadministration with lovastatin and simvastatin increases risk of rhabdomyolysis |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | Caution in liver disease; estolate formulation may cause cholestatic jaundice; adverse GI effects are common (give doses pc); discontinue use if nausea, vomiting, malaise, abdominal colic, or fever occur |
| Drug Name | Minocycline microspheres (Arestin) |
|---|---|
| Description | Used as an adjunct to scaling and root planing procedures for reduction of pocket depth in patients with adult periodontitis. May be used as part of a periodontal maintenance program that includes good oral hygiene and scaling and root planing. |
| Adult Dose | Insert a unit-dose cartridge into base of pocket and then press the thumb ring in the handle mechanism to expel the powder while gradually withdrawing the tip from the base of the pocket; the handle mechanism should be sterilized between patients; minocycline microspheres do not have to be removed, as they are bioresorbable, and no adhesive or dressing is required |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Discoloration of teeth may occur in last half of pregnancy, infancy, and childhood to age 8 y (do not use unless benefits outweigh risks); photosensitivity may occur; use of minocycline microspheres in acutely abscessed periodontal pocket has not been studied and is not recommended; use of minocycline microspheres may result in overgrowth of nonsusceptible microorganisms, including fungi; effect of treatment for > 6 mo has not been studied; use minocycline microspheres with caution in patients with history of predisposition to oral candidiasis; safety and efficacy of minocycline microspheres has not been established for treatment of periodontitis in patients with coexistent oral candidiasis; use of microspheres has not been clinically tested in patients with immunocompromise (eg, diabetes, chemotherapy, radiation therapy, HIV infection) |
| Drug Name | Doxycycline (Periostat) |
|---|---|
| Description | Inhibits protein synthesis and thus bacterial growth by binding to 30S and possibly 50S ribosomal subunits of susceptible bacteria. However, some studies have shown that doxycycline reduces elevated collagenase activity in gingival crevicular fluid of patients with adult periodontitis. Clinical significance of these findings is not known. |
| Adult Dose | Following scaling and root planing: 20 mg PO bid as an adjunct for <9 mo; safety beyond 12 mo and efficacy beyond 9 mo have not been established |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity; severe hepatic dysfunction |
| Interactions | Bioavailability decreases with antacids containing aluminum, calcium, magnesium, iron, or bismuth subsalicylate; tetracyclines can increase hypoprothrombinemic effects of anticoagulants; tetracyclines can decrease effects of oral contraceptives, causing breakthrough bleeding and increased risk of pregnancy |
| Pregnancy | D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Photosensitivity may occur with prolonged exposure to sunlight or tanning equipment; reduce dose in renal impairment; consider drug serum level determinations in prolonged therapy; tetracycline use during tooth development (last one half of pregnancy through age 8 y) can cause permanent discoloration of teeth; Fanconilike syndrome may occur with outdated tetracyclines |
| Drug Name | Clindamycin (Cleocin) |
|---|---|
| Description | Alternative for penicillin-allergic patients, a popular choice for severe infections or those recalcitrant with penicillin. |
| Adult Dose | 300 mg PO tid |
| Pediatric Dose | 6-8 mg/kg/d PO divided tid/qid |
| Contraindications | Documented hypersensitivity |
| Interactions | Increases duration of neuromuscular blockade, induced by tubocurarine and pancuronium; erythromycin may antagonize effects of clindamycin; antidiarrheals may delay absorption of clindamycin |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Adjust dose in severe hepatic dysfunction; no adjustment necessary in renal insufficiency; associated with severe and possibly fatal colitis |
This is shown to decrease bacterial counts in oral flora. It probably speeds resolution of gingivitis when combined with brushing and flossing.
| Drug Name | Chlorhexidine 0.12% oral rinse (PerioGard) |
|---|---|
| Description | Has bactericidal activity. |
| Adult Dose | 15 mL (1 tablespoon); swish in mouth for 30 s and expectorate bid |
| Pediatric Dose | Not established |
| Contraindications | Documented hypersensitivity |
| Interactions | None reported |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals |
| Precautions | May stain tooth enamel |
Patients with ANUG should be given a strong analgesic along with topical anesthetics and NSAIDs because pain control is very important in allowing the patient to eat and carry out toothbrushing, flossing, and other oral hygiene maneuvers necessary to eradicate the disease. NSAIDs also help to decrease pain. Although effects of NSAIDs in the treatment of pain tend to be patient-specific, ibuprofen usually is the DOC for initial therapy.
| Drug Name | Acetaminophen with codeine (Tylenol #3) |
|---|---|
| Description | Narcotic analgesic well tolerated by most patients; it may induce severe nausea and vomiting in patients particularly sensitive to the drug. |
| Adult Dose | 1-2 tab PO q6h prn pain |
| Pediatric Dose | 0.5-1 mg/kg/dose PO based on codeine q4-6h; 10-15 mg/kg/dose PO based on acetaminophen content; not to exceed 2.6 g/d of acetaminophen |
| Contraindications | Documented hypersensitivity |
| Interactions | Toxicity increases with CNS depressants or tricyclic antidepressants |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | Caution in patients dependent on opiates since this substitution may result in acute opiate-withdrawal symptoms; caution in severe renal or hepatic dysfunction |
| Drug Name | Ibuprofen (Ibuprin, Advil, Motrin) |
|---|---|
| Description | Used for pain relief and to decrease gingival inflammation. Use with care in patients with history of asthma or peptic ulcer disease. |
| Adult Dose | 600 mg PO q6-8h |
| Pediatric Dose | 5 mg/kg PO q6-8h |
| Contraindications | Documented hypersensitivity; peptic ulcer disease; recent GI bleeding or perforation; renal insufficiency; high risk of bleeding |
| Interactions | Coadministration with aspirin increases risk of inducing serious NSAID-related adverse effects; probenecid may increase concentrations and, possibly, toxicity of NSAIDs; may decrease effect of hydralazine, captopril, and beta-blockers; may decrease diuretic effects of furosemide and thiazides; monitor PT closely (instruct patients to watch for signs of bleeding); may increase risk of methotrexate toxicity; phenytoin levels may be increased when administered concurrently |
| Pregnancy | B - Fetal risk not confirmed in studies in humans but has been shown in some studies in animals D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus |
| Precautions | Caution in congestive heart failure, hypertension, and decreased renal and hepatic function; caution in anticoagulation abnormalities or during anticoagulant therapy |
These agents are helpful in providing pain control, which is very important in allowing the patient to carry out toothbrushing, flossing, and other oral hygiene maneuvers.
| Drug Name | Lidocaine viscous 2% (Dilocaine) |
|---|---|
| Description | An adjunctive therapy for pain control that decreases the permeability to sodium ions in neuronal membranes. This results in inhibition of depolarization, blocking the transmission of nerve impulses. |
| Adult Dose | 15 mL rinse PO and expectorate q6-8h prn |
| Pediatric Dose | >12 years: 15 mL rinse PO and expectorate q6-8h prn |
| Contraindications | Documented hypersensitivity; Adams-Stokes syndrome and Wolff-Parkinson-White syndrome |
| Interactions | None reported |
| Pregnancy | C - Fetal risk revealed in studies in animals but not established or not studied in humans; may use if benefits outweigh risk to fetus |
| Precautions | For external or mucous membrane use only; do not use in eyes |
Special thanks to Robert J. Lindberg, DMD, for images and excellent dental care.
| Media file 1: Healthy mouth and gingiva. Note the healthy light pink color of the gingiva. The intradental papillae are sharp and fill the intradental space. No local edema is present. Image courtesy of Robert J. Lindberg, DMD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 2: Moderate chronic gingivitis. Note that the papillae are edematous and blunted. They may bleed with brushing. Note areas of edema overlying some of the root areas. Pallor is seen in these areas. Image courtesy of Robert J. Lindberg, DMD. | |
![]() | View Full Size Image | Media type: Photo |
| Media file 3: Severe periodontal disease. Loss of the gingival tissue is seen, making the teeth appear long. Even more effacement of the papillae is present. Heaped up ridges are observed in the areas overlying the roots. Image courtesy of Robert J. Lindberg, DMD. | |
![]() | View Full Size Image | Media type: Photo |
Article Last Updated: Oct 15, 2008